Mechanism of Fluconazole Resistance in Candida krusei

National Committee for Clinical Laboratory Standards

Bruck, E. (1980) · PEDIATRICS · doi:10.1542/peds.65.1.187 · Cited by 14,736

The Carbon Monoxide-binding Pigment of Liver Microsomes

Omura, T., & Sato, R. (1964) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(20)82244-3 · Cited by 11,781

Increase in Candida krusei Infection among Patients with Bone Marrow Transplantation and Neutropenia Treated Prophylactically with Fluconazole

Wingard, J. R., Merz, W. G., Rinaldi, M. G., Johnson, T. R., Karp, J. E., & Saral, R. (1991) · New England Journal of Medicine · doi:10.1056/nejm199110313251803 · Cited by 937

Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters

Sanglard, D., Kuchler, K., Ischer, F., Pagani, J. L., Monod, M., & Bille, J. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.11.2378 · Cited by 815

Amino Acid Substitutions in the Cytochrome P-450 Lanosterol 14α-Demethylase (CYP51A1) from Azole-Resistant Candida albicans Clinical Isolates Contribute to Resistance to Azole Antifungal Agents

Sanglard, D., Ischer, F., Koymans, L. M. H., & Billé, J. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.2.241 · Cited by 465

Resistance to fluconazole and cross‐resistance to amphotericin B in Candida albicans from AIDS patients caused by defective sterol Δ5,6‐desaturation

Kelly, S. L., Lamb, D. C., Kelly, D. E., Manning, N. J., Loeffler, J., Hebart, H., Schumacher, U., & Einsele, H. (1997) · FEBS Letters · doi:10.1016/s0014-5793(96)01360-9 · Cited by 351

The presence of an R467K amino acid substitution and loss of allelic variation correlate with an azole-resistant lanosterol 14alpha demethylase in Candida albicans

White, T. C. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.7.1488 · Cited by 292

Deletion of the Candida glabrata ERG3 and ERG11 genes: effect on cell viability, cell growth, sterol composition, and antifungal susceptibility

Geber, A., Hitchcock, C. A., Swartz, J. E., Pullen, F. S., Marsden, K. E., Kwon-Chung, K. J., & Bennett, J. E. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.12.2708 · Cited by 203

The Mutation T315A in Candida albicans Sterol 14α-Demethylase Causes Reduced Enzyme Activity and Fluconazole Resistance through Reduced Affinity

Lamb, D. C., Kelly, D. E., Schunck, W., Shyadehi, A. Z., Akhtar, M., Lowe, D. J., Baldwin, B. C., & Kelly, S. L. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.9.5682 · Cited by 192

Interaction of azole antifungal antibiotics with cytochrome P -450-dependent 14α-sterol demethylase purified from Candida albicans

Hitchcock, C. A., Dickinson, K., Brown, S. B., Evans, E. G. V., & Adams, D. J. (1990) · Biochemical Journal · doi:10.1042/bj2660475 · Cited by 189

Antifungal Agents: Mode of Action, Mechanisms of Resistance, and Correlation of These Mechanisms with Bacterial Resistance

Ghannoum, M. A., & Rice, L. B. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.4.501 · Cited by 1,811

Azole Antifungal Resistance in Candida albicans and Emerging Non-albicans Candida Species

Whaley, S. G., Berkow, E. L., Rybak, J. M., Nishimoto, A. T., Barker, K. S., & Rogers, P. D. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.02173 · Cited by 900

Antifungal Drug Resistance: Molecular Mechanisms in Candida albicans and Beyond

Lee, Y., Puumala, E., Robbins, N., & Cowen, L. E. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00199 · Cited by 801

Nosocomial fungal infections: epidemiology, diagnosis, and treatment

Perlroth, J., Choi, B., & Spellberg, B. (2007) · Medical Mycology · doi:10.1080/13693780701218689 · Cited by 738

Resistance to Antifungal Agents: Mechanisms and Clinical Impact

Kanafani, Z. A., & Perfect, J. R. (2008) · Clinical Infectious Diseases · doi:10.1086/524071 · Cited by 619

Efflux-Mediated Antifungal Drug Resistance

Cannon, R. D., Lamping, E., Holmes, A. R., Niimi, K., Baret, P. V., Keniya, M. V., Tanabe, K., Niimi, M., Goffeau, A., & Monk, B. C. (2009) · Clinical Microbiology Reviews · doi:10.1128/cmr.00051-08 · Cited by 608

Antifungal drug resistance of pathogenic fungi

Kontoyiannis, D. P., & Lewis, R. E. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08162-x · Cited by 553

Fluconazole resistance in Candida species: a current perspective

Berkow, E., & Lockhart, S. (2017) · Infection and Drug Resistance · doi:10.2147/idr.s118892 · Cited by 542

Molecular basis of resistance to azole antifungals.

Lupetti, A. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(02)02280-3 · Cited by 449

Antifungal drug resistance among Candida species: mechanisms and clinical impact

Sanguinetti, M., Posteraro, B., & Lass‐Flörl, C. (2015) · Mycoses · doi:10.1111/myc.12330 · Cited by 394

Contribution of mutations in the cytochrome P450 14α-demethylase (Erg11p, Cyp51p) to azole resistance in Candida albicans

Marichal, P., Koymans, L., Willemsens, S., Bellens, D., Verhasselt, P., Luyten, W., Borgers, M., Ramaekers, F. C. S., Odds, F. C., & Vanden Bossche, H. (1999) · Microbiology · doi:10.1099/00221287-145-10-2701 · Cited by 382

Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: Time for harmonization of CLSI and EUCAST broth microdilution methods

Pfaller, M. A., Andes, D., Diekema, D. J., Espinel-Ingroff, A., & Sheehan, D. (2010) · Drug Resistance Updates · doi:10.1016/j.drup.2010.09.002 · Cited by 314

The rapid emergence of antifungal-resistant human-pathogenic fungi

Lockhart, S. R., Chowdhary, A., & Gold, J. A. W. (2023) · Nature Reviews Microbiology · doi:10.1038/s41579-023-00960-9 · Cited by 323

Regulation of multidrug resistance in pathogenic fungi

Morschhäuser, J. (2010) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2009.08.002 · Cited by 300

Interpretive Breakpoints for Fluconazole and Candida Revisited: a Blueprint for the Future of Antifungal Susceptibility Testing

Pfaller, M. A., Diekema, D. J., & Sheehan, D. J. (2006) · Clinical Microbiology Reviews · doi:10.1128/cmr.19.2.435-447.2006 · Cited by 300

An update on antifungal targets and mechanisms of resistance in Candidaalbicans

Akins, R. A. (2005) · Medical Mycology · doi:10.1080/13693780500138971 · Cited by 291

Antifungal Resistance in Pathogenic Fungi

Perea, S. H., & Patterson, T. F. (2002) · Clinical Infectious Diseases · doi:10.1086/344058 · Cited by 292

T2 Magnetic Resonance Enables Nanoparticle-Mediated Rapid Detection of Candidemia in Whole Blood

Neely, L. A., Audeh, M., Phung, N. A., Min, M., Suchocki, A., Plourde, D., Blanco, M., Demas, V., Skewis, L. R., Anagnostou, T., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005377 · Cited by 273

Antifungal and anti-biofilm activity of the first cryptic antimicrobial peptide from an archaeal protein against Candida spp. clinical isolates

Roscetto, E., Contursi, P., Vollaro, A., Fusco, S., Notomista, E., & Catania, M. R. (2018) · Scientific Reports · doi:10.1038/s41598-018-35530-0 · Cited by 276

Current Treatment Strategies for Disseminated Candidiasis

Spellberg, B. J., Filler, S. G., & Edwards, J. E. (2005) · Clinical Infectious Diseases · doi:10.1086/499057 · Cited by 254

Evolutionary Emergence of Drug Resistance in Candida Opportunistic Pathogens

Ksiezopolska, E., & Gabaldón, T. (2018) · Genes · doi:10.3390/genes9090461 · Cited by 230

Antimicrobial Peptide Synergies for Fighting Infectious Diseases

Mhlongo, J. T., Waddad, A. Y., Alberício, F., & de la Torre, B. G. (2023) · Advanced Science · doi:10.1002/advs.202300472 · Cited by 201

Virulence in Candida species

Haynes, K. (2001) · Trends in Microbiology · doi:10.1016/s0966-842x(01)02237-5 · Cited by 192

Voriconazole: A New Triazole Antifungal

Sabo, J., & Abdel‐Rahman, S. M. (2000) · Annals of Pharmacotherapy · doi:10.1345/aph.19237 · Cited by 184

Multidrug Resistance in Yeast Candida

Prasad, R., & Kapoor, K. (2004) · International review of cytology · doi:10.1016/s0074-7696(04)42005-1 · Cited by 182

Resistance of human fungal pathogens to antifungal drugs

Sanglard, D. (2002) · Current Opinion in Microbiology · doi:10.1016/s1369-5274(02)00344-2 · Cited by 178

Fungal–Metal Interactions: A Review of Toxicity and Homeostasis

Robinson, J. R., Isikhuemhen, O. S., & Anike, F. N. (2021) · Journal of Fungi · doi:10.3390/jof7030225 · Cited by 187

New pathogens, new tricks: emerging, drug‐resistant fungal pathogens and future prospects for antifungal therapeutics

Geddes‐McAlister, J., & Shapiro, R. S. (2018) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13739 · Cited by 162

Update on Candida krusei , a potential multidrug-resistant pathogen

Jamiu, A. T., Albertyn, J., Sebolai, O. M., & Pohl, C. H. (2020) · Medical Mycology · doi:10.1093/mmy/myaa031 · Cited by 173

Antifungal Efficacy during Candida krusei Infection in Non-Conventional Models Correlates with the Yeast In Vitro Susceptibility Profile

Scorzoni, L., de Lucas, M. P., Mesa-Arango, A. C., Fusco‐Almeida, A. M., Lozano, E., Cuenca‐Estrella, M., Mendes‐Giannini, M. J. S., & Zaragoza, Ó. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060047 · Cited by 150

Experimental Induction of Fluconazole Resistance in Candida tropicalis ATCC 750

Barchiesi, F., Calabrese, D., Sanglard, D., Falconi Di Francesco, L., Caselli, F., Giannini, D., Giacometti, A., Gavaudan, S., & Scalise, G. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.6.1578-1584.2000 · Cited by 145

Growth inhibition of Candida species and Aspergillus fumigatus by statins

Macreadie, I. G., Johnson, G., Schlosser, T., & Macreadie, P. I. (2006) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.2006.00370.x · Cited by 136

Responding to the Emergence of Antifungal Drug Resistance: Perspectives from the Bench and the Bedside

Beardsley, J., Halliday, C. L., Chen, S. C. ‐., & Sorrell, T. C. (2018) · Future Microbiology · doi:10.2217/fmb-2018-0059 · Cited by 131

Antifungal drug resistance mechanisms

Pemán, J., Cantón, E., & Espinel‐Ingroff, A. (2009) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.09.18 · Cited by 121

Susceptibilities ofCandidaSpecies to Amphotericin B and Fluconazole: The Emergence of Fluconazole Resistance inCandida tropicalis

Yang, Y.-L., Ho, Y.-A., Cheng, H.-H., Ho, M., & Lo, H. (2004) · Infection Control and Hospital Epidemiology · doi:10.1086/502294 · Cited by 119

Beach sand and the potential for infectious disease transmission: observations and recommendations

Solo‐Gabriele, H. M., Harwood, V. J., Kay, D., Fujioka, R. S., Sadowsky, M. J., Whitman, R. L., Wither, A., Caniça, M., Fonseca, R. C., Duarte, A., et al. (2015) · Journal of the Marine Biological Association of the United Kingdom · doi:10.1017/s0025315415000843 · Cited by 117

Fungal infections after bone marrow transplant

Wingard, J. R. (1999) · Transplantation and Cellular Therapy · doi:10.1053/bbmt.1999.v5.pm10371357 · Cited by 109

Multilaboratory study of epidemiological cutoff values for detection of resistance in eight Candida species to fluconazole, posaconazole, and voriconazole

Espinel-Ingroff, A., Pfaller, M. A., Bustamante, B., Canton, E., Fothergill, A., Fuller, J., Gonzalez, G. M., Lass-Flörl, C., Lockhart, S. R., Martin-Mazuelos, E., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02615-13 · Cited by 105

Identification and expression of multidrug resistancerelated ABC transporter genes in Candida krusei

Katiyar, S. K., & Edlind, T. D. (2001) · Medical Mycology · doi:10.1080/mmy.39.1.109.116 · Cited by 104

Understanding the Antifungal Mechanism of Ag@ZnO Core-shell Nanocomposites against Candida krusei

Das, B., Khan, M. I., Jayabalan, R., Behera, S. K., Yun, S., Tripathy, S. K., & Mishra, A. (2016) · Scientific Reports · doi:10.1038/srep36403 · Cited by 105

Abc1p Is a Multidrug Efflux Transporter That Tips the Balance in Favor of Innate Azole Resistance in Candida krusei

Lamping, E., Ranchod, A., Nakamura, K., Tyndall, J. D. A., Niimi, K., Holmes, A. R., Niimi, M., & Cannon, R. D. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01095-08 · Cited by 100

Emergence of Saccharomyces cerevisiae as a human pathogen

Murphy, A., & Kavanagh, K. (1999) · Enzyme and Microbial Technology · doi:10.1016/s0141-0229(99)00086-1 · Cited by 98

Molecular aspects of azole antifungal action and resistance

Lamb, D. C., Kelly, D. E., & Kelly, S. L. (1999) · Drug Resistance Updates · doi:10.1054/drup.1999.0112 · Cited by 97

Species identification of medically important fungi by use of real-time LightCycler PCR

Hsu, M.-C., Chen, K.-W., Lo, H., Chen, Y., Liao, M.-H., Lin, Y., & Li, S. (2003) · Journal of Medical Microbiology · doi:10.1099/jmm.0.05302-0 · Cited by 96

Genetic Basis for Differential Activities of Fluconazole and Voriconazole against Candida krusei

Fukuoka, T., Johnston, D. A., Winslow, C. A., de Groot, M. J., Burt, C., Hitchcock, C. A., & Filler, S. G. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.4.1213-1219.2003 · Cited by 97

Multiple amino acid substitutions in lanosterol 14α-demethylase contribute to azole resistance in Candida albicans

Favre, B., Ryder, N. S., & Didmon, M. P. (1999) · Microbiology · doi:10.1099/00221287-145-10-2715 · Cited by 95

Isavuconazole

Pettit, N. N., & Carver, P. L. (2015) · Annals of Pharmacotherapy · doi:10.1177/1060028015581679 · Cited by 86

Invasive Candidiasis: An Overview from Taiwan

Ruan, S., & Hsueh, P. (2009) · Journal of the Formosan Medical Association · doi:10.1016/s0929-6646(09)60091-7 · Cited by 85

Antifungal resistance in non- albicans Candida species

Collin, B. A., Clancy, C. J., & Nguyen, M. H. (1999) · Drug Resistance Updates · doi:10.1054/drup.1998.0059 · Cited by 81

Retrospective suspect screening reveals previously ignored antibiotics, antifungal compounds, and metabolites in Bangladesh surface waters

Angeles, L. F., Islam, S., Aldstadt, J., Saqeeb, K. N., Alam, M., Khan, M. A., Johura, F., Ahmed, S. I., & Aga, D. S. (2019) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2019.136285 · Cited by 80

Time to positivity of blood cultures of different Candida species causing fungaemia

Lai, C., Wang, C.-Y., Liu, W., Huang, Y., & Hsueh, P. (2012) · Journal of Medical Microbiology · doi:10.1099/jmm.0.038166-0 · Cited by 75

Diversity and antifungal susceptibility of yeasts from tropical freshwater environments in Southeastern Brazil

Medeiros, A. O., Kohler, L. M., Hamdan, J. S., Missagia, B. D. S., Barbosa, F. A. R., & Rosa, C. A. (2008) · Water Research · doi:10.1016/j.watres.2008.05.026 · Cited by 71

Canadian Clinical Practice Guidelines for Invasive Candidiasis in Adults

Bow, E. J., Evans, G. A., Fuller, J., Laverdière, M., Rotstein, C., Rennie, R. P., Shafran, S. D., Sheppard, D. C., Carle, S., Phillips, P., et al. (2010) · Canadian Journal of Infectious Diseases and Medical Microbiology · doi:10.1155/2010/357076 · Cited by 70

Risk factors for the development of invasive fungal infections in allogeneic blood and marrow transplant recipients

Rosa, G. R. D. L., Champlin, R. E., & Kontoyiannis, D. P. (2002) · Transplant Infectious Disease · doi:10.1034/j.1399-3062.2002.00010.x · Cited by 67

Susceptibilities to amphotericin B and fluconazole of Candida species in Taiwan Surveillance of Antimicrobial Resistance of Yeasts 2006

Yang, Y.-L., Wang, A.-H., Wang, C., Cheng, W.-T., Li, S., & Lo, H. (2008) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2008.01.011 · Cited by 66

In vitro Antifungal Effects of Berberine Against Candida spp. In Planktonic and Biofilm Conditions

Xie, Y., Liu, X., & Zhou, P. (2020) · Drug Design, Development and Therapy · doi:10.2147/dddt.s230857 · Cited by 63

The value of amphotericin B in the treatment of invasive fungal infections

Klepser, M. E. (2010) · Journal of Critical Care · doi:10.1016/j.jcrc.2010.08.005 · Cited by 64

Antifungal Prophylaxis in Liver Transplantation: A Systematic Review and Network Meta-Analysis

Evans, J., Morris, P. J., & Knight, S. R. (2014) · American Journal of Transplantation · doi:10.1111/ajt.12925 · Cited by 64

Enhanced antifungal activity of fluconazole conjugated with Cu-Ag-ZnO nanocomposite

Ghosh, M., Mandal, S., Roy, A., Chakrabarty, S., Chakrabarti, G., & Pradhan, S. K. (2019) · Materials Science and Engineering C · doi:10.1016/j.msec.2019.110160 · Cited by 61

Antifungal Resistance Among Candida Species

Klepser, M. E. (2001) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.21.12.124s.34511 · Cited by 61

Antifungal drugs and resistance: Current concepts

Nigam, P. K. (2015) · Our Dermatology Online · doi:10.7241/ourd.20152.58 · Cited by 60

Fluconazole resistance mechanisms inCandida krusei: The contribution of efflux-pumps

Guinea, J., Sánchez-Somolinos, M., Cuevas, Ó., Peláez, T., & Bouza, E. (2006) · Medical Mycology · doi:10.1080/13693780600561544 · Cited by 58

Azole‐resistant Candida spp. – emerging pathogens?

Tobudic, S., Kratzer, C., & Presterl, E. (2012) · Mycoses · doi:10.1111/j.1439-0507.2011.02146.x · Cited by 57

Fruits as the vehicle of drug resistant pathogenic yeasts

Lo, H., Tsai, S.-H., Chu, W.-L., Chen, Y.-Z., Zhou, Z.-L., Chen, H.-F., Lee, C.-F., & Yang, Y.-L. (2017) · Journal of Infection · doi:10.1016/j.jinf.2017.06.005 · Cited by 53

Colonization of Human Immunodeficiency Virus-Infected Outpatients in Taiwan with Candida Species

Hung, C., Yang, Y.-L., Lauderdale, T.-L. Y., McDonald, L. C., Hsiao, C., Cheng, H.-H., Ho, Y.-A., & Lo, H. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.4.1600-1603.2005 · Cited by 52

Development of Antifungal Therapies Using Nanomaterials

Niemirowicz, K., Durnaś, B., Piktel, E., & Bucki, R. (2017) · Nanomedicine · doi:10.2217/nnm-2017-0052 · Cited by 52

Candida albicans and Candida tropicalis in Oral Candidosis: Quantitative Analysis, Exoenzyme Activity, and Antifungal Drug Sensitivity

da Costa, K. R. C., Ferreira, J. C., Komesu, M. C., & Cândido, R. C. (2008) · Mycopathologia · doi:10.1007/s11046-008-9154-8 · Cited by 50

Susceptibilities to amphotericin B and fluconazole of Candida species in TSARY 2002

Yang, Y.-L., Li, S.-Y., Cheng, H.-H., & Lo, H. (2005) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2004.11.004 · Cited by 49

Emerging echinocandins for treatment of invasive fungal infections

Turner, M., Drew, R. H., & Perfect, J. R. (2006) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.11.2.231 · Cited by 49

Antifungal drug resistance: does it matter?

Rogers, T. R. (2002) · International Journal of Infectious Diseases · doi:10.1016/s1201-9712(02)90154-2 · Cited by 48

Emerging Issues in Antifungal Resistance

Perfect, J. R., & Ghannoum, M. A. (2020) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2020.05.003 · Cited by 44

Past, Present, and Future of Antifungal Drug Development

Shukla, P. K., Singh, P., Yadav, R. K., Pandey, S., & Bhunia, S. S. (2016) · Topics in medicinal chemistry · doi:10.1007/7355_2016_4 · Cited by 48

Emerging fungal resistance

Baddley, J. W., & Moser, S. A. (2004) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2004.05.003 · Cited by 47

Efflux as a mechanism of antimicrobial drug resistance in clinical relevant microorganisms: the role of efflux inhibitors

Willers, C., Wentzel, J. F., Plessis, D., Gouws, C., & Hamman, J. H. (2016) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2017.1265105 · Cited by 46

Fluconazole resistance rate of Candida species from different regions and hospital types in Taiwan.

Yang, Y.-L., Cheng, H.-H., Ho, Y.-A., Hsiao, C., & Lo, H. (2003) · PubMed · Cited by 45

Overexpression of MDR-1 and CDR-2 genes in fluconazole resistance of Candida albicans isolated from patients with vulvovaginal candidiasis

Rad, K., Falahati, M., Roudbary, M., Farahyar, S., & Nami, S. (2016) · Current Medical Mycology · doi:10.18869/acadpub.cmm.2.4.24 · Cited by 46

Increased coverage and high confidence in suspect screening of emerging contaminants in global environmental samples

Angeles, L. F., Singh, R. R., Vikesland, P. J., & Aga, D. S. (2021) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2021.125369 · Cited by 42

Candida krusei: biotechnological potentials and concerns about its safety

Yadav, J. S. S., Bezawada, J., Yan, S., Tyagi, R. D., & Surampalli, R. Y. (2012) · Canadian Journal of Microbiology · doi:10.1139/w2012-077 · Cited by 44

In VivoandIn VitroAcquisition of Resistance to Voriconazole by Candida krusei

Ricardo, E., Miranda, I. M., Faria‐Ramos, I., Silva, R. M., Rodrigues, A. G., & Pina‐Vaz, C. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02603-14 · Cited by 40

DNA microarray-based identification of bacterial and fungal pathogens in bloodstream infections

Yoo, S. M., Choi, J. Y., Yun, J. K., Choi, J., Shin, S., Lee, K., Kim, J. M., & Lee, S. Y. (2009) · Molecular and Cellular Probes · doi:10.1016/j.mcp.2009.09.003 · Cited by 40

Conventional and alternative antifungal therapies to oral candidiasis

Aníbal, P. C., Sardi, J. D. C. O., Peixoto, I. T. A., Moraes, J. J. D. C., & Höfling, J. F. (2010) · Brazilian Journal of Microbiology · doi:10.1590/s1517-83822010000400001 · Cited by 39

Genome-scale metabolic reconstruction of the non-model yeast Issatchenkia orientalis SD108 and its application to organic acids production

Suthers, P. F., Dinh, H. V., Fatma, Z., Shen, Y., Chan, S. H. J., Rabinowitz, J. D., Zhao, H., & Maranas, C. D. (2020) · Metabolic Engineering Communications · doi:10.1016/j.mec.2020.e00148 · Cited by 36

The pathophysiology and treatment of Candida sepsis

Spellberg, B. J., & Edwards, J. E. (2002) · Current Infectious Disease Reports · doi:10.1007/s11908-002-0005-3 · Cited by 37

Blood Stream Infections by Candida glabrata and Candida krusei: A Single-Center Experience

Choi, H. K., Jeong, S. J., Lee, H. S., Chin, B. S., Choi, S. H., Han, S. H., Kim, M. S., Kim, C. O., Choi, J. Y., Song, Y. G., et al. (2009) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2009.24.3.263 · Cited by 36

Antifungal amphiphilic kanamycins: new life for an old drug

Subedi, Y. P., Alfindee, M. N., Takemoto, J. Y., & Chang, C. T. (2018) · MedChemComm · doi:10.1039/c8md00155c · Cited by 34

Elevated minimum inhibitory concentrations to antifungal drugs prevail in 14 rare species of candidemia-causing Saccharomycotina yeasts

Stavrou, A. A., Hansen, A. P., Lackner, M., Lass‐Flörl, C., & Boekhout, T. (2020) · Medical Mycology · doi:10.1093/mmy/myaa005 · Cited by 37

Candidemia in Burn Patients: Figures and Facts

Pedrosa, A. F., & Rodrigues, A. G. (2011) · The Journal of Trauma: Injury, Infection, and Critical Care · doi:10.1097/ta.0b013e3181f2d4fb · Cited by 34

Epidemiology of candidaemia in a tertiary care university hospital: 10-year experience with 381 candidaemia episodes between 2001 and 2010.

Alp, S., Arikan‐Akdagli, S., Gulmez, D., Ascioglu, S., Uzun, O., & Akova, M. (2015) · Mycoses · doi:10.1111/myc.12349 · Cited by 32

Dynamics ofin vitro acquisition of resistance byCandida parapsilosisto different azoles

Silva, A. P., Costa‐de‐Oliveira, S., Silva-Dias, A., Pina‐Vaz, C., & Rodrigues, A. G. (2009) · FEMS Yeast Research · doi:10.1111/j.1567-1364.2009.00508.x · Cited by 35

The trend of susceptibilities to amphotericin B and fluconazole of Candida species from 1999 to 2002 in Taiwan

Yang, Y.-L., Li, S., Cheng, H.-H., & Lo, H. (2005) · BMC Infectious Diseases · doi:10.1186/1471-2334-5-99 · Cited by 33

Restriction Enzyme Analysis of Ribosomal DNA Shows that Candida inconspicua Clinical Isolates Can Be Misidentified as Candida norvegensis with Traditional Diagnostic Procedures

Majoros, L., Kardos, G., Belák, Á., Maráz, A., Asztalos, L., Csánky, E., Barta, Z., & Szabó, B. (2003) · Journal of Clinical Microbiology · doi:10.1128/jcm.41.11.5250-5253.2003 · Cited by 32

Overexpression of Both ERG11 and ABC2 Genes Might Be Responsible for Itraconazole Resistance in Clinical Isolates of Candida krusei

He, X., Zhao, M., Chen, J., Wu, R., Zhang, J., Cui, R., Jiang, Y., Chen, J., Cao, X., Xing, Y., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0136185 · Cited by 31

Do all candidemic patients need an ophthalmic examination?

Vinikoor, M. J., Zoghby, J., Cohen, K. L., & Tucker, J. D. (2013) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2012.12.014 · Cited by 31

Comparison of Two Commercially Available qPCR Kits for the Detection of Candida auris

Sattler, J., Noster, J., Brunke, A., Plum, G., Wiegel, P., Kurzai, O., Meis, J. F. G. M., & Hamprecht, A. G. (2021) · Journal of Fungi · doi:10.3390/jof7020154 · Cited by 32

Microbiological Screening of Irish Patients with Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy Reveals Persistence of Candida albicans Strains, Gradual Reduction in Susceptibility to Azoles, and Incidences of Clinical Signs of Oral Candidiasis without Culture Evidence

McManus, B. A., McGovern, E., Moran, G. P., Healy, C. M., Nunn, J., Fleming, P., Costigan, C., Sullivan, D. J., & Coleman, D. C. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.00026-11 · Cited by 30

A comparative study on production of extracellular hydrolytic enzymes of Candida species isolated from patients with surgical site infection and from healthy individuals and their co-relation with antifungal drug resistance

Erum, R., Samad, F., Khan, A., & Kazmi, S. U. (2020) · BMC Microbiology · doi:10.1186/s12866-020-02045-6 · Cited by 29

Antifungal Activity of Capric Acid, Nystatin, and Fluconazole and Their In Vitro Interactions Against Candida Isolates from Neonatal Oral Thrush

Khalandi, H., Masoori, L., Farahyar, S., Delbandi, A. A., Raiesi, O., Farzanegan, A., Khalandi, G., Mahmoudi, S., Erfanirad, T., & Falahati, M. (2020) · Assay and Drug Development Technologies · doi:10.1089/adt.2020.971 · Cited by 28

Identification of Candida Species and Antifungal Susceptibility in Cancer Patients with Oral Lesions in Ahvaz, Southern West of Iran

Maheronnaghsh, M., Fatahinia, M., Dehghan, P., & Teimoori, A. (2020) · Advanced Biomedical Research · doi:10.4103/abr.abr_214_19 · Cited by 28

Candidemia in Children

Silvester, E. J., Watanabe, M., Pittet, L. F., Boast, A., Bryant, P. A., Haeusler, G. M., Daley, A. J., Curtis, N. C., & Gwee, A. (2021) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000003082 · Cited by 27

Distribution and antifungal susceptibility ofCandidaspecies isolated from different age populations in Taiwan

Yang, Y.-L., Cheng, H.-H., & Lo, H. (2006) · Medical Mycology · doi:10.1080/13693780500401213 · Cited by 28

Inhibition and interaction of cytochrome P450 ofCandida kruseiwith azole antifungal drugs

Venkateswarlu, K., Denning, D. W., & Kelly, S. (1997) · Medical Mycology · doi:10.1080/02681219780000821 · Cited by 31

Fluconazole resistance mechanisms inCandida krusei: The contribution of efflux-pumps

Guinea, J., Sánchez-Somolinos, M., Cuevas, Ó., Peláez, T., & Bouza, E. (2006) · Medical Mycology · doi:10.1080/13693780600561544 · Cited by 58

Short Communication Fluconazole resistance mechanisms in Candida krusei: The contribution of efflux-pumps

Guinea, J., Cuevas, O., & Bouza, E. (2016)

Reduced accumulation of drug in Candida krusei accounts for itraconazole resistance

Venkateswarlu, K., Denning, D. W., Manning, N. J., & Kelly, S. L. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.11.2443 · Cited by 58

Genetic Basis for Differential Activities of Fluconazole and Voriconazole against Candida krusei

Fukuoka, T., Johnston, D. A., Winslow, C. A., de Groot, M. J., Burt, C., Hitchcock, C. A., & Filler, S. G. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.4.1213-1219.2003 · Cited by 97